CAS NO: | 1446261-44-4 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Pamiparib (BGB-290) is an orally active, potent, highly selectivePARPinhibitor, withIC50values of 0.9 nM and 0.5 nM forPARP1andPARP2, respectively. Pamiparib has potentPARPtrapping, and capability to penetrate the brain, and can be used for the research of various cancers including the solid tumor[1][2]. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | Pamiparib shows potent DNA-trapping activity with anIC50of 13 nM. In the cellular assays, Pamiparib inhibits intracellular PAR formation with anIC50of 0.24 nM. Tumor cell lines with homologous recombination defects are profoundly sensitive to Pamiparib. Pamiparib is highly active both in vitro and in vivo in BRCA mutant tumors[3]. | ||||||||||||||||
体内研究 (In Vivo) | Pamiparib suppresses PARP activity in patient-derived glioblastoma multiforme and small-cell-lung cancer xenografts, and potentiates the effects of Temozolamide. In vivo activities of Pamiparib, and its combination activity with chemotherapies in patient biopsy derived small cell lung cancer (SCLC) xenograft models[4]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 298.31 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C16H15FN4O | ||||||||||||||||
CAS 号 | 1446261-44-4 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 50 mg/mL(167.61 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|